Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 04272N102 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Orbimed Advisors LLC
13D/A
Amendment 2
|
5.8% |
10/8/2026
Event 10/6/2026
|
|
| Orbimed Advisors LLC | 5.8% | ||
| OrbiMed Capital GP VIII LLC | 2.9% | ||
| OrbiMed Asia GP IV, L.P. | 2.9% | ||
| OrbiMed Advisors IV Limited | 2.9% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 6.8% |
7/27/2026
Event 6/30/2026
|
|
|
FMR LLC
13G/A
Amendment 2
|
6.8% |
5/6/2026
Event 3/31/2026
|
|
| FMR LLC | 6.8% | ||
| Abigail P. Johnson | 6.8% | ||
|
Sofinnova Venture Partners IX, L.P.
13G/A
Amendment 1
|
4.1% |
3/5/2026
Event 12/31/2025
|
|
| Sofinnova Venture Partners XI, L.P. ("SVP XI") | 4.1% | ||
| Sofinnova Management XI, L.P. ("SM XI LP") | 4.1% | ||
| Sofinnova Management XI, L.L.C. ("SM XI LLC") | 4.1% | ||
| Dr. James I. Healy ("Healy") | 4.1% | ||
| Dr. Maha Katabi ("Katabi") | 4.1% | ||
|
Infinitum Asset Management, LLC
13G/A
Amendment 1
|
9.9% |
2/17/2026
Event 12/31/2025
|
|
| Infinitum Asset Management, LLC | 9.9% | ||
| Infinitum Partners GP, LLC | 9.9% | ||
| Infinitum Cayman Master, Ltd. | 9.9% | ||
| Hillhouse Investment Management, Ltd. 13G/A Amendment 1 | 9.5% |
2/17/2026
Event 12/31/2025
|
|
| Vanguard Group Inc 13G/A Amendment 1 | 4.5% |
1/30/2026
Event 12/31/2025
|
|
| BlackRock, Inc. 13G | 5.6% |
1/21/2026
Event 12/31/2025
|
|
|
Octagon Capital Advisors LP
13G/A
Amendment 1
|
4.9% |
11/14/2025
Event 9/30/2025
|
|
| Octagon Capital Advisors LP | 4.9% | ||
| Octagon Investments Master Fund LP | 1.9% | ||
| Octagon Private Opportunities Fund LP | 2.0% | ||
| Octagon Special Opportunities Fund LP - Series 4 | 1.0% | ||
| Ting Jia | 4.9% | ||
|
FMR LLC
13G/A
Amendment 1
|
8.4% |
11/5/2025
Event 9/30/2025
|
|
| FMR LLC | 8.4% | ||
| Abigail P. Johnson | 8.4% | ||
| Vanguard Group Inc 13G | 5.0% |
10/30/2025
Event 9/30/2025
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 4.9% |
10/17/2025
Event 9/30/2025
|
|
| HBM Healthcare Investments (Cayman) Ltd. 13G | 5.4% |
10/15/2025
Event 10/8/2025
|
|
|
Infinitum Asset Management, LLC
13G
|
9.9% |
8/13/2025
Event 5/1/2025
|
|
| Infinitum Asset Management, LLC | 9.9% | ||
| Infinitum Cayman Master, Ltd. (Fund) | 9.9% | ||
| Infinitum Partners GP, LLC | 9.9% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 1
|
7.5% |
8/13/2025
Event 8/11/2025
|
|
| Orbimed Advisors LLC | 7.5% | ||
| OrbiMed Capital GP VIII LLC | 3.7% | ||
| OrbiMed Asia GP IV, L.P. | 3.7% | ||
| OrbiMed Advisors IV Limited | 3.7% | ||
|
Suvretta Capital Management, LLC
13G/A
Amendment 1
|
9.9% |
8/13/2025
Event 6/30/2025
|
|
| Suvretta Capital Management, LLC | 9.9% | ||
| Averill Master Fund, Ltd. | 8.7% | ||
| Aaron Cowen | 9.9% | ||
|
Infinitum Asset Management, LLC
13G
|
6.1% |
5/15/2025
Event 5/1/2025
|
|
| Infinitum Asset Management, LLC | 6.1% | ||
| Infinitum Cayman Master, Ltd. | 6.1% | ||
| Infinitum Partners GP, LLC | 6.1% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 1.78 k | $53.9 k |
| 2026 Q2 | 165 | 47.1 M | $1.63 B |
| 2026 Q1 | 146 | 42.1 M | $969 M |
| 2025 Q4 | 125 | 40.1 M | $810 M |
| 2025 Q3 | 110 | 38.6 M | $713 M |
| 2025 Q2 | 101 | 33.6 M | $732 M |
| 2025 Q1 | 84 | 29.1 M | $539 M |
| 2024 Q4 | 81 | 28.5 M | $757 M |
| 2024 Q3 | 70 | 25.9 M | $612 M |
| 2024 Q2 | 57 | 21.7 M | $405 M |
| 2024 Q1 | 57 | 21.9 M | $390 M |